39 results about "Benserazide" patented technology

Disclosed herein are methods for identifying compounds that enhance base excision repair, as well as compounds identified thereby and methods of using such compounds in the interception of malignancy, i.e. the prevention of progression of a disease from a state of susceptibility to active disease. Exemplified compounds are acetohexamide and related compounds, as well as benserazide and analogs thereof. Exemplified malignancies are those of human breast cells carrying mutations, in particular, SUM149 cells and HCC1937 cells, which cells carry BRCA1 mutations.

Prostate cancer comes in various forms and has proven difficult to treat. Provided herein are various methods and compositions for treating all forms of prostate cancers with dopa decarboxylase (DDC) inhibitors. These dopa decarboxylase inhibitors include carbidopa (α-Methyl-dopahydrazine), MFMD (α-monofluoromethyldopa), NSD-1015 (3-hydroxybenzylhydrazine), Methyldopa (L-α-Methyl-3,4-dihydroxyphenylalanine) or benserazide, and the inhibitors may be used in combination. DDC inhibitors may also be used to inhibit the progression of prostate cancer to androgen-independence and neuroendocrine prostate cancer.

The invention belongs to the field of drug preparations, and particularly relates to a method for improving the stability of an oral administration solid composition containing benserazide hydrochloride. The benserazide hydrochloride is a peripheral decarboxylase inhibitor, and the benserazide hydrochloride and levodopa are always prepared into a compound preparation and are combined to be mainly used for treating the Parkinson' s disease (essential paralysis agitans), and postencephalitic or the symptomatic Parkinson' s syndrome (non-drug-induced paralysis agitans syndrome) combined with cerebral arteriosclerosis. The property of the benserazide hydrochloride is extremely unstable, and the benserazide hydrochloride is extremely sensitive to change of PH, ray, temperature and humidity. Since the ways of wet granulation and vacuum drying are adopted, the stability of the benserazide hydrochloride in an oral administration solid preparation containing the benserazide hydrochloride can be improved.

The invention relates to an application of a microsphere composition containing an antiparkinsonism drug to preparation of a medicine for preventing and treating parkinson diseases and complicating diseases of parkinson diseases. The microsphere composition containing the antiparkinsonism drug is selected from benserazide microspheres, L-dopa methyl ester microspheres, the L-dopa methyl ester microspheres and the benserazide microspheres, or L-dopa methyl ester and benserazide mixing drug microspheres. The invention also provides a microsphere combination medicament containing the antiparkinsonism drug. The invention explores novel medical application for the microsphere combination medicament containing the antiparkinsonism drug and develops a novel application field. The microsphere combination medicament containing the antiparkinsonism drug of the invention is safe and nontoxic, has strong pharmacological action and indicates good medicinal prospect.

The invention discloses a levodopa/benserazide orally disintegrating tablet and a preparation method thereof. The tablet comprises the main drugs including levodopa and benserazide and the auxiliary materials including microcrystalline cellulose, mannitol, lactose, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, sodium cyclamate, menthol, aerosol and magnesium stearate. The tablet of the invention can effectively treat the Parkinson disease or Parkinsonism syndrome, is convenient to take, good in mouthfeel, quick in disintegration, fast in absorption and high in bioavailability and provides convenience for the Parkinson disease or Parkinsonism syndrome patients who have difficulty in taking the whole tablet or feel inconvenient to take the tablet.

The invention relates to a benserazide sustained-release microspherical composition, which comprises the following components by weight percent: 40%-99% of a degradable hydrophobic polymer and 1%-60% of benserazide. The invention also provides a preparation method of the benserazide sustained-release microspherical composition. The invention can overcome the instability of benserazide during the storage process and improve the pharmaceutical therapeutic effect on patients. The method for preparing the microspherical composition can avoid the defects of low entrapment rate of the conventional W/O and W/O/W, and environmental pollution of S/O/O caused by serious burst release. In the invention, the grain diameter of the microspherical composition prepared by the method can be controlled according to different demands without environmental pollution, and the influence on the therapeutic effect of benserazide can be prevented. The surfaces of the obtained granules are smooth and rounded, the granules are regular without adhesion, the grain diameter can be regulated and controlled from 1mum to 5mum as required, and freeze-drying powder of the granules is white, exquisite and loose, is not collapsed and adhered, and has good redispersibility.

The invention particularly relates to application of BZE as an antibacterial agent. Aiming at the current situations that drug-resistant bacteria are increased year by year, the research and development period of antibacterial drugs is long, and the marketing speed is low at present, non-antibiotic drugs with an antibacterial effect are developed in the field and used for coping with the troublesome current situation that the drug-resistant bacteria are difficult to treat. Based on the technical thought, BZE is screened and verified to have a good antibacterial effect, and has a good in-vitrocomplete inhibition effect on MRSA, MDRAB and CRKP with high drug resistance. Based on the research result, the BZE is expected to be developed as an effective component of a broad-spectrum antibacterial drug, and has good clinical treatment and economic significance.

Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.

The invention relates to a pharmaceutical composition of levodopa/benserazide/folic acid compounds and a purpose thereof, and belongs to the technical field of pharmacy. The pharmaceutical composition comprises the levodopa with medical dose, the benserazide with the medical dose, the folic acid compounds with the medical dose and a carrier which can be accepted in the pharmacy. The dose of the levodopa is 100-300 mg, the dose of the benserazide is 30-70 mg, and the dose of the folic acid compounds is 0.2-1.6 mg. The pharmaceutical composition of the levodopa/the benserazide/the folic acid compounds and the purpose thereof have the advantages of enhancing the curative effect of Parkinson disease resistance and improving the quality of life of a patient through the synergistic effect of multiple target points; being capable of effectively preventing and lowering the occurring risk of cerebral apoplexy of a Parkinson disease patient through a homocysteine (Hcy) target point; and in addition, enabling the patient to take medicine conveniently.

The invention belongs to the technical field of medicine. The invention in particular relates to the applicatoin of benserazide (The International Nonproprietary Names for Pharmaceutical Substances (INN) is Benserazide) as an alpha-glucosidase inhibitor, and a structure-based computational simulation screening method. Benserazide can be stably combined with an active site of alpha-glucosidase to inhibit the activity of alpha-glucosidase, so that the effect of reducing blood sugar is achieved. According to the invention, based on a thought of new use of old drugs, FDA-approved drugs are subjected to pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation processes, and it is found that benserazide can be stably combined at an active site of alpha-glucosidase, and in-vitro experiments show that benserazide is an alpha-glucosidase inhibitor, so that the new application of the benserazide in reducing blood sugar is excavated. The invention not only provides a new angle for benserazide as a hypoglycemic drug, but also provides an example for rapid development of a novel alpha-glucosidase inhibitor.

The present invention provides conjugates comprising a sugar such as mannitol and one or more L-DOPA and/or DOPA decarboxylse inhibitors including, inter alia, L-DOPA, carbidopa, benserazide, or a combination thereof, wherein the sugar is conjugated to the carboxyl group of the L-DOPA and/or DOPA decarboxylse inhibitor/ s) via a hydroxyl group of the sugar. The present invention further provides related pharmaceutical compositions and methods of producing the conjugates, as well as methods of use for treating medical disorders responsive to dopamininergic stimulation such as movement disorders including, inter alia, Parkinson's Disease.

The invention discloses a method for synthesizing benserazide hydrochloride by using fixed bed hydrogenation equipment, which is characterized in that a compound 1 reacts with an amino protective agent to carry out an amino protection reaction, so that the subsequent purification is easy, and the dosage of hydrazine hydrate in the synthesis method is small; according to the method, fixed bed hydrogenation equipment is used for synthesis, a fixed bed reactor is filled with a solid catalyst or a solid to realize a heterogeneous reaction process, the catalyst in the fixed bed reactor is relatively fixed, a reaction liquid flows through a bed layer, and the reaction liquid flows through the bed layer by adjusting the flow rate and the reaction pressure; qualified products can be obtained after reaction liquid flows out of the fixed bed, continuous production can be achieved, product deterioration caused by long-time contact of the products and the catalyst can be avoided, the same amount of products can be produced due to continuous production, the reactor size can be very small, the safety problem caused by high-pressure reaction is greatly reduced, the amount of the catalyst used in the reaction is less, and the production cost is reduced.

The invention provides a method for detecting the content of a benserazide impurity A in a levodopa and benserazide hydrochloride compound preparation. According to the method, a hydrophilic chromatographic column is adopted, an aqueous solution containing sodium heptanesulfonate and monopotassium phosphate and having a pH value of 1.7-9.0 is adopted as a mobile phase A, methanol is adopted as a mobile phase B, and a staged gradient elution method is adopted to separate a benserazide impurity A and determine the content of the benserazide impurity A in a levodopa and benserazide hydrochloridecompound preparation. The method is good in separation effect, simple to operate, high in recovery rate, high in sensitivity and wide in linear range, and has important practical significance in the aspect of quality control in the preparation process of the preparation.

The invention discloses a blood-brain barrier high-permeability hexokinase inhibitor as well as a synthesis method and application thereof. Wherein the inhibitor has a structure as shown in a formula I. The compound provided by the invention can solve the problems that benserazide molecules have high polarity and have a plurality of phenolic hydroxyl groups, so that the bioavailability is low and the benserazide is difficult to penetrate through a blood-brain barrier. Therefore, the inhibitor disclosed by the invention has the advantages that the cell permeability and bioavailability are remarkably improved, so that the effect of treating the Alzheimer's disease, the Parkinson's disease and the multiple sclerosis is achieved by penetrating through the blood brain barrier, and the inhibitor has a wide application prospect in the field of central nervous system diseases.

Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.